Business Wire

Proteor to Expand Lower Limb Prosthetics Portfolio Through Its Acquisition of Freedom Innovations Assets

9.10.2020 21:58:00 EEST | Business Wire | Press release

Share

Proteor USA, LLC, a wholly owned subsidiary of the France based, Proteor Group, has signed an agreement with Ottobock to acquire a significant portion of the lower limb prosthetics portfolio of Freedom Innovations which demonstrates Proteor’s continued commitment and investment in the worldwide prosthetic industry. The agreement was reached by Proteor and Ottobock at the end of September 2020 and the proposed transaction is anticipated to close by the end of 2020.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201009005566/en/

Under the agreement, Proteor will expand substantially its lower limb prosthetics portfolio and acquire a range of Freedom Innovations’ flagship products, including the Plié3 microprocessor knee, the Kinnex and Kinterra ankles, and the Agilix, Highlander, Dynadapt, Sierra and Pacifica feet products.

Both Proteor and Freedom Innovations share a similar mission to increase the independence and well-being of people who use their products by offering innovative, high-performance solutions that deliver security, stability, and comfort for a reasonable price. Through the acquisition of a significant portion of Freedom Innovations, Proteor is eager to combine the teams in the United States and Europe and expand globally, thereby providing a clear choice to prosthetists and their patients for enhanced outcomes.

“We strongly believe in the long-term benefits of this move for the people we serve around the world. By combining the expertise of our teams in the US and Europe, the momentum we generate will continue to build Proteor’s presence within the O&P community,” said Edouard Archambeaud, COO and member of the Managing Board of Proteor.

Matthew Swiggum, President and CEO of Proteor USA states, “We are dedicated to providing inventive, dependable products to the orthotic and prosthetic community that offer increased independence with an outstanding product portfolio. Working with the passionate and skilled team at Freedom Innovations is a pleasure we’re all looking forward to.”

For Proteor, the proposed transaction will reinforce its positioning and growth strategy worldwide, while creating synergies within innovation platforms, significant continuous R&D investment, and a focus on mechatronic lower limb solutions. This proposed transaction will further build upon Proteor’s presence in the United States lower limb prosthetics market, already strengthened by Proteor’s prior acquisition of Ability Dynamics’ RUSH Foot portfolio, which further illustrates Proteor’s commitment to its markets worldwide.

The terms of the proposed transaction between Proteor and Ottobock remain subject to the final approval of the Commissioners of the U.S. Federal Trade Commission (FTC) and are meant to satisfy Ottobock’s obligations under the Order from the FTC to divest certain assets from the U.S. company Freedom Innovations. Once approval from the FTC is obtained, Proteor USA will integrate a significant number of Freedom Innovations team members in manufacturing, sales, marketing, R&D and clinical from Gunnison, Utah; Irvine, California; and Germany.

About Proteor
Proteor, an independent family-company, was established 105 years ago with its headquarters in Dijon, France. Proteor operates in the O&P market with three key areas of activities: software’s, components and custom-made devices. Thanks to continuous investments in innovation, many medical and scientific partnerships, and day to day cooperation with CPOs, Proteor enjoys a recognized expertise all over the O&P community.

For additional information visit http://proteorusa.com/.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media:
Sophie Desbois
Sophie.desbois@proteor.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

TVS Motor Company Returns to EICMA With New Models for Europe26.10.2026 13:45:00 EET | Press release

TVS Motor Company (TVSM), a global leader in two- and three-wheeler manufacturing, returns to EICMA in Milan this November, one year after its debut at the world’s largest two-wheeler exhibition. The company will present new models for Europe at a press conference on Tuesday, 3 November at 10:00 CET. The TVS stand is in Hall 18, Stand I64. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261026990290/en/ TVS Motor Company will present new models for Europe at a press conference on Tuesday, 3 November at 10:00 CET at EICMA this year. EICMA 2025 marked the beginning of TVS Motor's European growth journey. Since then, the company has focused on establishing the foundations for long-term success, building its dealer network, aftersales capabilities and customer support infrastructure across key markets. In Italy, its first European market, TVS now works with around 100 dealers. Retail sales in Italy are up 110% this year to Septem

Two-Year Data of Pimicotinib Demonstrated Durable Tumor Control and Sustained Improvement in TGCT Symptoms and Joint Function26.10.2026 13:00:00 EET | Press release

Merck, a leading science and technology company, today announced new two-year follow-up results from the Phase 3 MANEUVER study evaluating pimicotinib in patients with tenosynovial giant cell tumor (TGCT). The study showed that among patients initially randomized to pimicotinib, improvements in symptoms and joint function were observed as early as Week 5, sustained through two years, and continued to improve over time. Tumor responses remained robust1 and durable,2 and the safety profile was consistent with previous analyses. The findings are being presented today in the Sarcoma poster session at the European Society for Medical Oncology (ESMO) Congress 2026 (Presentation # 3747P). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261022786567/en/ David Weinreich, Global Head of R&D and Chief Medical Officer for the Healthcare business of Merck "For people living with TGCT, the impact of the disease is often felt through persis

WHOOP and Samuel Ross MBE Unveil Layer 2 of PROJECT TERRAIN26.10.2026 12:30:00 EET | Press release

WHOOP, the human performance brand, today announced Layer 2 of PROJECT TERRAIN, its multiyear collaboration with British designer Samuel Ross MBE and his design atelier, SR_A. Building on the sold out debut collection launched in March 2026, Layer 2 expands PROJECT TERRAIN to its next season connecting lifestyle and performance for movement, adaptability and zone based training. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261026029587/en/ WHOOP and Samuel Ross MBE Unveil Layer 2 of PROJECT TERRAIN While the first PROJECT TERRAIN collection harnessed dense cities and modern training grounds, Layer 2 explores performance through material, silhouette and tactility. Drawing on the textures, conditions, and flux of the natural world, the collection introduces a newly developed system of WHOOP bands, Italian technical apparel, outerwear, and accessories designed to move between urban and outdoor settings. Performance extends be

Bleeding gums? Don't ignore the warning signs – the first stage of gum disease can be reversed26.10.2026 12:28:00 EET | Press release

Gums bleeding when brushing can happen to any of us, and it is easy to ignore. But blood in the sink is a sign that something is not right with your mouth. Bleeding gums often indicate gingivitis, the earliest and most common form of gum disease. The good news: gingivitis can be reversed with proper oral hygiene. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261022835650/en/ Oral-B iO Left untreated, gingivitis can progress into periodontitis, a more severe stage of gum disease that can only be managed, not reversed, and can lead to losing teeth over time. Healthy gums matter beyond the mouth, too. Oral health and systemic health are deeply interconnected, with inflammation and bacteria from oral diseases contributing to conditions such as heart disease, diabetes and dementia. "Gums bleeding when brushing can happen to any of us. When they do, it shouldn't be ignored," said Eva Castro Perea, who holds a degree in dentistry

Merz Therapeutics Presents New Phase 2 PaiNT Data in Peripheral Neuropathic Pain at IASP 202626.10.2026 09:00:00 EET | Press release

Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced the presentation of new clinical and translational research in peripheral neuropathic pain (PNP) at the International Association for the Study of Pain (IASP) 2026 World Congress in Bangkok, Thailand, taking place from 26 to 30 October. The research spans new Phase 2 findings on incobotulinumtoxinA in postherpetic neuralgia (PHN) and post-surgical/post-traumatic neuropathic pain (PS/PTNP), as well as preclinical studies exploring potential biological mechanisms involved in effects of incobotulinumtoxinA on PNP models, highlighting Merz Therapeutics’ growing presence in neuropathic pain. In the PHN population of the Phase 2 PaiNT trial, results over 20 weeks favored incobotulinumtoxinA versus placebo treatment. In an exploratory analysis of average daily pain (ADP) intensity, the greatest difference between treatment groups was observed at Week 6 (adjusted mean difference, −1.14 points; p=0.0488).

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye